KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2025)

Historic Cash & Current Investments for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $21.6 million.

  • Bionano Genomics' Cash & Current Investments rose 920.48% to $21.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.6 million, marking a year-over-year increase of 920.48%. This contributed to the annual value of $20.2 million for FY2024, which is 6978.78% down from last year.
  • As of Q3 2025, Bionano Genomics' Cash & Current Investments stood at $21.6 million, which was up 920.48% from $16.5 million recorded in Q2 2025.
  • Bionano Genomics' 5-year Cash & Current Investments high stood at $362.1 million for Q1 2021, and its period low was $16.5 million during Q2 2025.
  • Moreover, its 5-year median value for Cash & Current Investments was $77.1 million (2023), whereas its average is $127.9 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first skyrocketed by 434621.81% in 2021, then plummeted by 7218.73% in 2024.
  • Over the past 5 years, Bionano Genomics' Cash & Current Investments (Quarter) stood at $250.6 million in 2021, then crashed by 54.84% to $113.2 million in 2022, then crashed by 41.01% to $66.8 million in 2023, then plummeted by 69.79% to $20.2 million in 2024, then increased by 7.15% to $21.6 million in 2025.
  • Its Cash & Current Investments stands at $21.6 million for Q3 2025, versus $16.5 million for Q2 2025 and $18.2 million for Q1 2025.